Bibliography
- UNSICKER K, SUTER-CRAZZALORA C, KRIEGLSTEIN K: Growth factor function in the development and maintenance of midbrain dopaminergic neurones: concepts, facts and prospects for TGF-6. Ciba Found Symp. (1996) 196:70-80 (Discussion 80–84).
- OLANOW CW, TATTON WG: Etiology and pathogenesis of Parkinson's disease. Ann. Rev. Neurosa (1999) 22:123–144.
- UNSICKER K: Growth factors in Parkinson's disease. Prog. Growth Factor Res. (1994) 5(1):73–87.
- MARSDEN CD, OLANOW CW: The causes of Parkinson's disease are being unraveled and rational neuroprotec-tive therapy is close to reality. Ann. Neurol (1998) 44\(Suppl. 0:S189–196.
- PAHWA R, MARJAMA J, MCGUIRE D et al.: Pharmacoki-netic comparison of Sinemet and Atamet (generic carbidopa/levodopa): a single-dose study. Mov. Disord. (1996) 11(4):427–430.
- DOOLEY M, MARKHAM A: Pramipexole. A review of its use in the management of early and advanced Parkin-son's disease. Drugs Aging (1998) 12(6):495–514.
- GOTTWALD MD, BAINBRIDGE JL, DOWLING GA, AMINOFF MJ, ALLDREDGE BK: New pharmacotherapy for Parkinson's disease. Ann. Pharmacother. (1997) 31(10):1205–1217.
- DA-PRADA M: New approaches to the treatment of age-related brain disorders. Can. J. Neurol Sci. (1991) 18\(Suppl. 3):384–386.
- BLANCHET PJ: Rationale for use of dopamine agonists in Parkinson's disease: review of ergot derivatives. Can. J. Neurol. Sci. (1999) 26\(Suppl. 2):S21–26.
- RABEY JM: Second generation of dopamine agonists: pros and cons. J. Neural. Transm. Suppl. (1995) 45:213–224.
- VILLA RF, ARNABOLD R, GHIGINI B, GORINI A: Parkinson-like disease by 1-methy1-4-pheny1-1,2,3,6-tetrahydropyridine (MPTP) toxicity in Macaca fascicularis: synaptosomal metabolism and action of dihydroergocriptine. Neurochem. Res. (1994) 19(3):229–236.
- STOCCHI F, NORDERA G, MARSDEN CD: Strategies for treating patients with advanced Parkinson's disease with disastrous fluctuations and dyskinesias. Neuropharmacol. (1997) 20 (2):95–115.
- GLENNER CG, WONG CW: Alzheimer's disease and down's syndrome: sharing of a unique cerebrovas-cular amyloid fibril protein) derived by proteolysis of amyloid precursor protein (APP). Biochem. Biophys. Res. Commun. (1984) 122:1131–1135.
- KANG J, LEMAIRE HG, UNTERBECK A et al.: The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature (1987) 325:733–736.
- KOH JY, YANG LL, COTMAN CW: Beta-amyloid proteinincreases the vulnerability of cultured cortical neurones to excitotoxic damage. Brain Res. (1990) 533:315–320.
- MULTHAUP G, SCHLICKSUPP A, HESSE L et al.: Theamyloid precursor protein of Alzheimer's disease in the reduction of copper(I) to copper(0. Science (1996) 271:1406–1409.
- KRUMAN I, BRUCE-KELLER AJ, BREDESEN D, WAEG G, MATTSON MP: Evidence that 4-hydroxynonenal mediates oxidative stress-induced neuronal apoptosis. j Neurosa (1997) 17:5089–5100.
- SAYRE LM, ZELASKO DA, HARRIS PL, PERRY G, SALOMON RG, SMITH MA: 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J. Neurochem. (1 9 9 7) 68(2)2092–2097.
- MARSHALL KA, DANIEL SE, CAIRNS N, JENNER P, HALLIWELL B: Upregulation of the anti-apoptotic protein Bc1-2 may be an early event in neurodegenera-tion: studies on Parkinson's and incidental Lewy body disease. Biochem. Biophys.Res. Commun. (1997) 240(1)84–87.
- BEDNER E, LI X, GORCZYCA W, MELAMED MR, DARZYNKIEWICZ Z: Analysis of apoptosis by laser scanning cytometry. Cytometty (1999) 35 (3):181–195
- NICOTERA P, LEIST M, MANZO L: Neuronal cell death: ademise with different shapes. TIPS (1999) 20:46–51.
- •Critical review including potential risks of anti-apoptotic treatment.
- DEIGNER HP, KINSCHERF R: Modulating Apoptosis: Current Applications and Prospects for Future Drug Development. Curr. Med. Chem. (1999) 6:399–414.
- DIXON SC, ARAH IN: Apoptosis: a novel therapeutic tool. Exp. Opin. Invest. Drugs (1998) 7(6):889–904.
- DENNER L: Caspases in apoptotic death. Exp. Opin. Invest. Drugs (1999) 8(0:37–50.
- PELENGARIS SA, EVAN GI: Matters of life and cell death. Rev. Neurol. Paris (1997) 153(8-9):470–477.
- FRIEDLANDER RM, YUAN J: ICE, neuronal apoptosis and neurodegeneration. Cell Death Differ. (1 9 9 8) 5 (10):823–831.
- OLANOW CW: An introduction of the free radical hypothesis in Parkinson's disease. Ann. Neurol. (1992) 32:S2–S9.
- GORMAN AM, MCGOWAN A, O'NEILL C, COTTER T: Oxidative stress and apoptosis in neurodegeneration. Neurol Sci. (1996) 139:45–52.
- MULTHAUP G, RUPPERT T, SCHLICKSUPP A et al.:Reactive oxygen species and Alzheimer's disease. Biochem. Pharmacol. (1997) 54(5)533–539.
- FRANCE-LANORD V, BRUGG B, MICHEL PP, AGID Y, RUBERG M: Mitochondrial free radical signal in ceramide-dependent apoptosis: a putative mechanism for neuronal death in Parkinson's disease. J. Neurochem. (1997) 69(4):1612–1621.
- TATTON WG, OLANOW CW: Apoptosis in neurodegen-erative diseases: the role of mitochondria. Biochim. Biophys. Acta. (1999) 1410(2):195–213.
- TEMLETT JA: Parkinson's disease: biology and aetiology. Curr. Opin. Neurol. (1996) 9(4):303–307.
- TATTON WG, CHALMERS-REDMAN RM: Mitochondria in neurodegenerative apoptosis: an opportunity for therapy? Ann. Neurol (1998) 44 (Suppl. 1):S134–141.
- WULLNER U, KORNHUBER J, WELLER M et al.: Cell death and apoptosis regulating proteins in Parkinson's disease, a cautionary note. Acta Neuropathol. Bed. (1999) 97 (4):408–412.
- VYAS S, JAVOY-AGID F, HERRERO MT et al.: Expression of Bc1-2 in adult human brain regions with special reference to neurodegenerative disorders. J. Neurochem. (1997) 69 (1) :223–231.
- PEROVIC S, BOHM M, MEESTERS E et al.: Pharma-cological intervention in age-associated brain disorders by Flupirtine: Alzheimer's and prion diseases. Mech. Ageing Dev. (1998) 1O1(1–2):1–19.
- •Opens the perspective of pharmacological treatment of AD by an approved drug.
- HUNOT S, BRUGG B, RICARD D et al.: Nuclear transloca-tion of NF-kappaB is increased in dopaminergic neurones of patients with Parkinson's disease. Proc. Natl. Acad. Sci. USA (1997) 94(14):7531–7536.
- HUNOT S, DUGAS N, FAUCHEUX B et al.: Fcepsi-lonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. J. Neurosci. (1999) 19(9)3440–3447.
- RUBERG M, FRANCE-LANORD V, BRUGG B et al: Neuronal death caused by apoptosis in Parkinson's disease. Rev. Neurol. Paris. (1997) 153(8-9):499–508.
- WHITE AR, BUSH Al, BEYREUTHER K, MASTERS CL CAPPAI R: Exacerbation of copper toxicity in primary neuronal cultures depleted of cellular glutathione. Neurochem. (1999) 72(5)2092–2098.
- •Supports the importance of oxidative stress in the aetiology of AD.
- FERRARI G, YAN YC, GREENE LA: N-acetylcysteine (D-and L- stereoisomers) prevents apoptotic death of neuronal cells. J. Neurosci. (1995) 15:2857–2866.
- RATAN RR, MURPHY TH, BARABAN JM: Oxidative stress induces apoptosis in embryonic cortical neurones. J. Neurochem. (1994) 62 (1) :376–379.
- SEATON TA, COOPER JM, SCHAPIRA AH: Free radical scavengers protect dopaminergic cell lines from apoptosis induced by complex I inhibitors. Brain Res. (1997) 777(1-2):110–118.
- KIKUCHI S, SHINPO K, MORIWAKA F, MAKITA Z, MIYATA T, TASHIRO K: Neurotoxicity of methylglyoxal and 3-deoxyglucosone on cultured cortical neurones: synergism between glycation and oxidative stress, possibly involved in neurodegenerative diseases. J. Neurosci. Res. (1999) 57(2):280–289.
- MARTINEZ M, MARTINEZ N, HERNANDEZ Al, FERRANDIZML: Hypothesis: can N-acetylcysteine be beneficial in Parkinson's disease? Life Sci. (1999) 64 (15):1253–1257.
- PEARCE RK, OWEN A, DANIELS, JENNER P, MARSDEN CD: Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. J. Neural. Transm. (1997) 104(6-7):661–677.
- ARIGA T, JARVIS WD, YU RK: Role of sphingolipid-mediated cell death in neurodegenerative diseases. J. Lipid Res. (1998) 39(1):1–16.
- LUO Y, UMEGAKI H, WANG X, ABE R, ROTH GS: Dopamine induces apoptosis through an oxidation-involved SAPK/JNK activation pathway. J. Biol. Chem. (1998) 273M3756–3764.
- ZIV I, OFFEND, BARZILAI A et al: Modulation of controlmechanisms of dopamine-induced apoptosis-a future approach to the treatment of Parkinson's disease? J. Neural. Transm. Suppl. (1997) 49:195–202.
- KITAMURA Y, KOSAKA T, KAKIMURA JI et al.: Protectiveeffects of the antiparkinsonian drugs talipexole and pramipexole against 1-methy1-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells. Mol. Pharmacol. (1998) 54:1046–1054.
- MORDENTE A, MARTORANA GE, MINOTTI G, GIARDINAB: Antioxidant properties of 2,3-dimethoxy-5-methy1-6-(10-hydroxydecy0-1,4-benzoquinone (idebenone). Chem. Res. Toxicol. (1998) 11(1):54–63.
- TAKEDA CHEMICAL INDUSTRIES LTD.: Takeda Annual Report 1998. Overview of product status.
- THAL LJ: Clinical and preclinical information of anti-oxidant: idebenone and vitamin E. Neurobiol. Aging (1998) 19\(Suppl. 4):56.
- GUTZMANN H, HADLER D: Clinical evaluation of idebenone in the long-term treatment of Alzheimer's disease. Neurobiol. Aging (1998) 19\(Suppl. 4):55.
- PEREIRA C, SANTOS MS, OLIVEIRA C: Involvement of oxidative stress on the impairment of energy metabo-lism induced by A beta peptides on PC12 cells: protec-tion by antioxidants. Neurobiol Dis. (1999) 6(3)209–219.
- HIRAI K, HAYAKO H, KATO K, MIYAMOTO M: Idebenone protects hippocampal neurones against amyloid beta-peptide-induced neurotoxicity in rat primary cultures. Naunyn Schmiedebergs Arch. Pharmacol. (1998) 358(5)582–585.
- CIVENNI G, BEZZI P, TROTTI D, VOLTERRA A, RACAGNI G: Inhibitory effect of the neuroprotective agent idebenone on arachidonic acid metabolism in astrocytes. Eur. j Pharmacol. (1999) 370 (2) :161–167.
- SCAVINI C, ROZZA A, LANZA E, FAVALLI L, RACAGNI G, BRUNELLO N: Effect of idebenone on in vivo serotonin release and serotonergic receptors in young and aged rats. Eur. Neuropsychopharmacol. (1996) 6(2):95–102.
- PAPPOLLA MA, CHYAN YJ, BOZNER P et al.: Dual anti-amyloidogenic and antioxidant properties of melatonin: A new therapy for Alzheimer's disease? Alzheimer's Disord. (1999):661–669.
- PAPPOLLA MA, SOS M, OMAR RA et al.: Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide. J. Neurosci. (1997) 1 7 (5) :1683–1690.
- TAN DX, MANCHESTER LC, REITER RJ, QI W, KIM SJ,EL-SOKKARY GH: Melatonin protects hippocampal neurones in vivo against kainic acid-induced damage in mice. J. Neurosci. Res. (1998) 54 (3):382–389.
- SIMONS M, KELLER P, DE-STROOPER B, BEYREUTHER K, DOTTI CG, SIMONS K: Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurones. Proc. Natl. Acad. Sci. USA (1 9 9 8) 95(11)6460–6464.
- HARTMANN T, BIEGER SC, BROHL B et al.: Distinct sites of intracellular production for Alzheimer's disease A 640/42 amyloid peptides. Nature Med. (1997) 3(9):1016–1020.
- PILLOT T, DROUET B, QUEILLE S et al: The nonfibrillaramyloid 6-peptide induces apoptotic neuronal cell death: involvement of its C-terminal fusogenic domain. J. Neurochem. (1999) 73(4):1626–1634.
- SCORZIELLO A, MEUCCI 0, CALVANI M, SCHETTINI G: Acetyl-L-carnitine arginine amide prevents beta 25-35-induced neurotoxicity in cerebellar granule cells. Neurochem. Res. (1997) 22(3):257–265.
- DOBBS RJ, CHARLETT A, PURKISS AG, DOBBS SM, WELLER C, PETERSON DW: Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism. Acta Neurol. Scand. (1999) 100(0:34–41.
- HERR I, WILHELM D, BOHLER T, ANGEL P, DEBATIN KM:Activation of CD95 (APO-1/Fas) signalling by ceramide mediates cancer therapy-induced apoptosis. EMBO J. (1997) 16(20):6200–6208.
- BERRIDGE MJ: Lymphocyte activation in health anddisease. Grit. Rev. Immunol (1997) 17(2):155–178.
- MORETTI S, ALESSE E, DI-MARZIO L et al. Effect of L-carnitine on human immunodeficiency virus-1 infection-associated apoptosis: a pilot study. Blood (1998) 9i(10):3817–3824.
- HERR I, MARTIN-VILLALBA A, KURZ E et al.: FK506prevents stroke-induced generation of ceramide and apoptosis signalling. Brain Res. (1999) 826(2):210–219.
- CLAUS R, RUSSWURM S, MEISNER M, KINSCHERF R, DEIGNER HP: Modulation of the ceramide level, a novel therapeutic concept? Current Drug Targets (In Press).
- SUBBARAMA1AH K, CHUNG WJ, DANNENBERG AJ: Ceramide regulates the transcription of cyclooxygenase-2. J. Biol. Chem. (1998) 273:32943–32949.
- VANE JR, BOTTING RM: Mechanism of action of antiin-flammatory drugs. Int. J. Tissue React. (1998) 20 (1):3–15.
- PASINETTI GM, AISEN PS: Cyclooxygenase-2 expressionis increased in frontal cortex of Alzheimer's disease brain. Neuroscience (1998) 87 (2):319–324.
- HO L, PIERONI C, WINGER D, PUROHIT DP, AISEN PS,PASINETTI GM: Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer's disease. J. Neurosci. Res. (1 9 9 9) 57 (3):295–303.
- LUKIW WJ, BAZAN NG: Strong nuclear factor-kappaB-DNA binding parallels cyclooxygenase-2 gene transcription in aging and in sporadic Alzheimer's disease superior temporal lobe neocortex. J. Neurosci. Res. (1998) 53(5):583–592.
- TOCCO G, FREIRE-MOAR J, SCHREIBER SS, SAKHI SH,AISEN PS, PASINETTI GM: Maturational regulation and regional induction of cyclooxygenase-2 in rat brain: implications for Alzheimer's disease. Exp. Neurol. (1997) 144(2)339–349.
- ROGERS J, KIRBY LC, HEMPELMAN SR et al.: Clinical trialof indomethacin in Alzheimer's disease. Neurology (1993) 43(8):1609–1611.
- VANE J: Towards a better aspirin. Nature (1994)367(6460):215–216.
- BREITNER JC, WELSH KA, HELMS MJ et al.: Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine 112 blocking drugs. Neurobiol. Aging (1995) 16(4):523–530.
- MOLLER HJ: Therapeutic strategies based on immuno-logical hypotheses of Alzheimer's disease. J. Neural. Transm. Suppl. (1998) 54:175–186.
- STEWART WF, KAWAS C, CORRADA M, METTER EJ: Riskof Alzheimer's disease and duration of NSAID use. Neurology (1997) 48(3):626–632.
- KITAMURA Y, SHIMOHAMA S, KOIKE H et al.: Increasedexpression of cyclooxygenases and peroxisome proliferator-activated receptor-gamma in Alzheimer's disease brains. Biochem. Biophys. Res. Commun. (1999) 254(3)582–586.
- O'BANION MK: Cyclooxygenase-2: molecular biology,pharmacology and neurobiology. Grit. Rev. Neurobiol (1999) 13(0:45–82.
- LIPSKY PE: The clinical potential of cyclooxygenase-2-specific inhibitors. Am. J. Med. (1999) 106(5B):515–575.
- RICH JB, RASMUSSON DX, FOLSTEIN MF, CARSON KA,KAWAS C, BRANDT J: Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology (1995) 45 (1):51–55.
- SCHARF S, MANDER A, UGONI A, VAJDA F, CHRISTO-PHIDIS N: A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology (1999) 53(1):197–201.
- IN'T VELD BA, LAUNER LJ, HOES AW et al.: NSAIDs andincident Alzheimer's disease. The Rotterdam Study. Neurobiol. Aging (1998) 19(6):607–611.
- BAZAN NG: The neuromessenger platelet-activatingfactor in plasticity and neurodegeneration. Prog. Brain Res. (1998) 118:281–291.
- DANNHARDT G, KOHL BK: The glycine site on the NMDA receptor: structure-activity relationships and possible therapeutic applications. Curr. Med. Chem. (1998) 5(4):253–263.
- TENNETI L, D'EMILIA DM, TROY CM, LIPTON SA: Role ofcaspases in N-methyl-D-aspartate-induced apoptosis in cerebrocortical neurones. J. Neurochem. (1998) 71(3)946–959.
- FRANKIEWICZ T, POTTER B, BASHIR ZI, COLLINGRIDGEGL, PARSONS CG: Effects of memantine and MK-801 on NMDA-induced currents in cultured neurones and on synaptic transmission and LTP in area CA1 of rat hippocampal slices. Br. J. Pharmacol. (1996) 117 (4):689–697.
- WENK GL, DANYSZ W, MOBLEY SL: MK-801, memantineand amantadine show neuroprotective activity in the nucleus basalis magnocellularis. Eur. J. Pharmacol. (1995) 293(3):267–270.
- DI-PAOLA R, UITTI RJ: Early detection of Parkinson'sdisease. Implications for treatment. Drugs Aging (1996) 9(3):159–168.
- PARSONS CG, DANYSZ W, QUACK G: Memantine is aclinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - a review of preclinical data. Neuropharmacology (1999) 38(6):735–767.
- KORNHUBER J, WELLER M: Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implica-tions for neuroprotective pharmacotherapy. Psychiatry (1997) 41(2):135–144.
- QUACK G, HESSELINK M, DANYSZ W, SPANAGEL R: Microdialysis studies with amantadine and memantine on pharmacokinetics and effects on dopamine turnover. J. Neural. Transm. Suppl. (1995) 46:97–105.
- MOGI M, TOGARI A, KONDO T et al.: Brain-derivedgrowth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease. Neurosci. Lett. (1999) 270(0:45–48.
- LINGOR P, UNSICKER K, KRIEGLSTEIN K: Midbraindopaminergic neurones are protected from radical induced damage by GDF-5 application. J. Neural. Transm. (1999) 106(2):139–144.
- •Provides the concept of GDF-5 as potential drug for PD treatment.
- FARKAS LM, JASZAI J, UNSICKER K, KRIEGLSTEIN K: Characterization of bone morphogenetic protein family members as neurotrophic factors for cultured sensory neurones. Neuroscience (1999) 92 (1):227–235.
- FARKAS LM, SCHEUERMANN S, POHL J, UNSICKER-K, KRIEGLSTEIN K: Characterization of growth/differen-tiation factor 5 (GDF-5) as a neurotrophic factor for cultured neurones from chicken dorsal root ganglia. Neurosci. Lett. (1997) 236(2):120–122.
- KRIEGLSTEIN K, REUSS B, MAYSINGER D, UNSICKER K: Short communication: transforming growth factor-beta mediates the neurotrophic effect of fibroblast growth factor-2 on midbrain dopaminergic neurones. Eur. j Neurosci. (1998) 10(8):2746–2750.
- FLANDERS KC, REN RF, LIPPA CF: Transforming growth factor-betas in neurodegenerative disease. Prog. Neurobiol. (1998) 54(0:71–85.
- SCHOBER A, HERTEL R, ARUMAE U et al. Glial cell line-derived neurotrophic factor rescues target-deprived sympathetic spinal cord neurones but requires transforming growth factor-beta as cofactor in vivo. J. Neurosci. (1999) 19(6):2008–2015.
- KRIEGLSTEIN K, HENHEIK P, FARKAS L et al Glial cell line-derived neurotrophic factor requires transforming growth factor-beta for exerting its full neurotrophic potential on peripheral and CNS neurones. J. Neurosci. (1998) 18(23):9822–9834.
- HUTTER-PAIER B, GRYGAR E, WINDISCH M: Death of cultured telencephalon neurones induced by glutamate is reduced by the peptide derivative Cerebrolysin. J. Neural. Transm. Suppl. (1996) 47:267–273.
- WINDISCH M, GSCHANES A, HUTTER-PATER B: Neurotrophic activities and therapeutic experience with a brain derived peptide preparation. J. Neural. Transm. Suppl. (1998) 53:289–298.
- FRANCIS-TURNER L, VALOUSKOVA V: Nerve growth factor and nootropic drug Cerebrolysin but not fibroblast growth factor can reduce spatial memory impairment elicited by fimbria-fornix transection: short-term study. Neurosci. Lett. (1996) 202 (3):193–196.
- GSCHANES A, WINDISCH M: Early postnatal treatment with peptide preparations influences spatial naviga-tion of young and adult rats. Behav. Brain Res. (1999) 100(1-2):161–166.
- REINPRECHT I, GSCHANES A, WINDISCH M, FACHBACH G: Two peptidergic drugs increase the synaptophysin immunoreactivity in brains of 24-month-old rats. Histochem. J. (1999) 31(6)395–401.
- LOMBARDI VR, WINDISCH M, GARCIA M, CACABELOS R: Effects of Cerebrolysin on in vitro primary microglial and astrocyte rat cell cultures. Methods Find Exp. Clin. Pharmacol. (1999) 21(5):331–338.
- MASLIAH E, ARMASOLO F, VEINBERGS I, MALLORY M, SAMUEL W: Cerebrolysin ameliorates performance deficits and neuronal damage in apolipoprotein E-deficient mice. Pharmacol. Biochem. Behav. (1999) 62 (2):239–245.
- RUTHER E, RITTER R, APECECHEA M, FREYTAG S, WINDISCH M: Efficacy of the peptidergic nootropic drug cerebrolysin in patients with senile dementia of the Alzheimer type (SDAT). Pharmacopsychiatry (1994) 27(1)32–40.
- THORNBERRY NA, LAZEBNIK Y: Caspases: enemies within. Science (1998) 281(5380:1312–1326.
- SHIVERS BD, BOXER PA, KEANE KM et al.: Contribution of the ICE family to neurodegeneration. Ann. NY Acad. ScL (1998) 840:59–64.
- HAASS C: Apoptosis. Dead end for neurodegeneration? Nature (1999) 399(6733):204–207.
- •A timely assessment of the chances of anti-apoptotic treatment for neurodegenerative diseases.
- LEBLANC A, LIU H, GOODYER C, BERGERON C, HAMMOND J: Caspase-6 role in apoptosis of human neurones, amyloidogenesis and Alzheimer's disease. J. Biol. Chem. (1999) 274 (33):23426–23436.
- CHAN SL, GRIFFIN WS, MATTSON MP: Evidence for caspase-mediated cleavage of AMPA receptor subunits in neuronal apoptosis and Alzheimer's disease. J. Neurosci. Res. (1999) 57(3):315–323.
- GERVAIS FG, XU D, ROBERTSON GS et al.: Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-beta precursor protein and amyloidogenic A beta peptide formation. Cell (1999) 97(3)395–406.
- •Highlights the potential of caspase-inhibition for AD treatment.
- PELLEGRINI L, PASSER BJ, TABATON M, GANJEI JK, D'ADAMIO L: Alternative, non-secretase processing of Alzheimer's beta-amyloid precursor protein during apoptosis by caspase-6 and -8. J. Biol. Chem. (1999) 274(30:21011–21016.
- NAKAGAWA T, ZHU H, MORISHIMA N et al.: Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-0. Nature (2000) 403:98–103.
- WEIDEMANN A, PALIGA K, DURRWANG U et al.: Formation of stable complexes between two Alzheimer's disease gene products: presenilin-2 and beta-amyloid precursor protein. Nature Med. (1997) 3 (3):328–332.
- KIM TW, PETTINGELL WH, JUNG YK, KOVACS DM, TANZI RE: Alternative cleavage of Alzheimer-associated presenilins during apoptosis by a caspase-3 family protease. Science (1997) 277(5324)373–376.
- TANZI RE: Of calcium, caspases and cognitive decline. Nature Med. (1998) 4(10:1127–1178.
- WOLFE MS, XIA W, OSTASZEWSKI BL, DIEHL TS, KIMBERLY WT, SELKOE DJ: Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature (1999) 398(6727):513–517.
- DIEHLMANN A, IDA N, WEGGEN S et al.: Analysis of presenilin 1 and presenilin 2 expression and processing by newly developed monoclonal antibodies. J. Neurosci. Res. (1999) 56(0405–419.
- UETSUKI T, TAKEMOTO K, NISHIMURA I etal.: Activation of neuronal caspase-3 by intracellular accumulation of wild-type Alzheimer amyloid precursor protein. J. Neurosci. (1999) 19(16)6955–6964.
- HOLTZMAN DM, DESHMUKH M: Caspases: a treatment target for neurodegenerative disease? Nature Med. (1997) 3(9):954–955.
- SCHIERLE GS, HANSSON 0, LEIST M, NICOTERA P, WIDNER H, BRUNDIN P: Caspase inhibition reduces apoptosis and increases survival of nigral transplants. Nature Med. (1999) 5(0:97–100.
- FINK K, ZHU J, NAMURA S et al.: Prolonged therapeutic window for ischemic brain damage caused by delayed caspase activation. J. Cereb. Blood Flow Metab. (1998) 18(101071–1076.
- AKAO Y, NAKAGAWA Y, MARUYAMA W, TAKAHASHI T, NAOI M: Apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, is mediated by activation of caspase 3. Neurosci. Lett. (1999) 267 (3):153–156.
- HOUENOU LJ, TURNER PL, LI L, OPPENHEIM RW, FESTOFF BW: A serine protease inhibitor, protease nexin I, rescues motoneurons from naturally occurring and axotomy-induced cell death. Proc. Natl. Acad. ScL USA (1995) 92(3):895–899.
- MOURADIAN MM, CHASE TN: Gene therapy for Parkin-son's disease: an approach to the prevention or pallia-tion of levodopa-associated motor complications. Exp. Neurol. (1997) 144:51–57.
- KANG UJ: Potential of gene therapy for Parkinson's disease: neurobiologic issues and new developments in gene transfer methodologies. Mov. Disord. (1998) 13 (Suppl. 1)59–72.
- GOLLAPUDI L, OBLINGER MM: STable transfection of PC12 cells with estrogen receptor (ERalpha): protec-tive effects of estrogen on cell survival after serum deprivation. J. Neurosci. Res. (1999) 56:99–108.
- LINNIK MD, ZAHOS P, GESCHWIND MD, FEDEROFF HJ: Expression of bc1-2 from a defective herpes simplex virus-1 vector limits neuronal death in focal cerebral ischemia. Stroke (1995) 26: 1670-1674.
- DE STROOPER B, ANNAERT W, CUPERS P et al.: A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature (1999) 398 (6727):518–522.
- SELKOE DJ: Translating cell biology into therapeutic advances in Alzheimer's disease. Nature (1999) 399(6738 Suppl):A23–31.
- •Recognises the role of advancements in cell biology for AD treatment.
- LYSAGHT MJ, FRYDEL B, GENTILE F, EMERICH D, WINN S: Recent progress in immunoisolated cell therapy. J. Biochem. (1994) 56(2):196–203.
- BEAL MF, GROWDON JH: CSF neurotransmitter markers in Alzheimer's disease. Prog. Neuropsychophar-macol. Biol. Psychiatry (1986) 10:259–270.
- DESHMUKH M, JOHNSON EM: Programmed cell death in neurones: focus on the pathway of nerve growth factor deprivation-induced death of sympathetic neurones. Mol. Pharmacol (1997) 51 (6)897–906.
- MOLLER JC, SAUTTER J, KUPSCH A: Potential of neurotrophic factors in therapy of Parkinson's disease. J. Neural. Transm. Suppl. (1996) 48:103–112.
- KOLIATOS VE: Biological therapies for Alzheimer's disease: focus on trophic factors. Neurobiol. (1996) 10(2)205–238.
- SCHINSTINE M, FIORE DM, WINN SR, EMERICH DF: Polymer-encapsulated Schwannoma cells expressing human nerve growth factor promote the survival of cholinergic neurones after a fimbria-fornix transec-tion. Cell Transplantation (1995) 4(1):93–102.
- WINN SR, HAMMANG JP, EMERICH DF, LEE A, PALMITER RD, BAETGE EE: Polymer-encapsulated cells geneti-cally modified to secrete human nerve growth factor promote the survival of axotomized septal cholinergic neurones. Proc. Natl. Acad. Sci. USA (1 9 9 4) 91(6):2324–2328.
- EMERICH DF, WINN SR, HARPER J, HAMMANG JP, BAETGE EE, KORDOWER JH: Implants of polymer-encapsulated human NGF-secreting cells in the nonhuman primate: rescue and sprouting of degener-ating cholinergic basal forebrain neurones. J. Comp. Neurol (1994) 349(0:148–164.
- KORDOWER JH, WINN SR, LIU YT et al.: The aged monkey basal forebrain: rescue and sprouting of axotomized basal forebrain neurones after grafts of encapsulated cells secreting human nerve growth factor. Proc. Natl. Acad. Sci. USA (1994) 91(23):10898–10902.
- HOFFMAN D, BREAKFIELD XO, SHORT MP, AEBISCHER P: Transplantation of a polymer-encapsulated cell line genetically engineered to release NGF. Exp. Neurol. (1993) 122(0:100–106.
- EMERICH DF, WINN SR, HAMMANG JP, KORDOWER JH, FRYDEL BR, BAETGE EE: Transplantation of polymer-encapsulated cells genetically modified to secrete human nerve growth factor prevents the loss of degenerating cholinergic neurones in rats and nonhuman primates. Cell Transplantation (1994) 3 (3):212.
- CYTOTHERAPEUTICS: Update on core delivery system technologies. London, UK. IDdb Meeting Report (April 15, 1997).
- WINN SR, LINDNER MD, LEE A, HAGGETT G, FRANCIS JM, EMERICH DF: Polymer-encapsulated genetically modified cells continue to secrete human nerve growth factor for over one year in rat ventricles: behavioral and anatomical consequences. Exp. Neurol. (1996) 140(2):126–138.
- MIDDLEMISS PJ, GLASKY AJ, RATHBONE MP, WERSTUIK E, HINDLEY S, GYSBERS J: AIT-082, a unique purine derivative, enhances nerve growth factor mediated neurite outgrowth from PC12 cells. NeuroscL Lett. (1995) 199(2):131–134.
- KINSCHERF R, CLAUS R, WAGNER M et al.: Apoptosis caused by oxidized LDL is manganese superoxide dismutase and p53 dependent. FASEB J. (1998) 12 (6):461–467.
- CIFONE MG, ALESSE E, DI-MARZIO L et al. Effect of L-carnitine treatment in vivo on apoptosis and ceramide generation in peripheral blood lymphocytes from AIDS patients. Proc. Assoc. Am. Physicians (1997) 109(2):146–153.
- DI-MARZIO L, ALESSE E, RONCAIOLI P et al.: Influence of L-carnitine on CD95 cross-lining-induced apoptosis and ceramide generation in human cell lines: correla-tion with its effects on purified acidic and neutral sphingomyelinases in vitro. Proc. Assoc. Am. Physicians (1997) 109(2):154–163.
- ANDRIEU-ABADIE N, JAFFREZOU JP, HATEM S, LAURENT G, LEVADE T, MERCADIER JJ: L-carnitine prevents doxorubicin-induced apoptosis of cardiac myocytes: role of inhibition of ceramide generation. FASEB J. (1999) 13(12):1501–1510.
- BROOKS JO 3RD, YESAVAGE JA, CARTA A, BRAVI D: Acetyl L-carnitine slows decline in younger patients with Alzheimer's disease: a reanalysis of a double-blind, placebo-controlled study using the trilinear approach. Int. Psychogeriatr. (1998) 10(2):193–203.
- Riluzole for amyotrophic lateral sclerosis. Drug Ther. Bull. (1997) 35(2):11–12.
- BENAVIDES J, CAMELIN JC, MITRANI N et al.: 2-Amino-6-trifluoromethoxy benzothiazole, a possible antago-nist of excitatory amino acid neurotransmission. II. Biochemical properties. Neuropharmacology (1985) 24:1085–1092.
- BENOIT E, ESCANDE D: Riluzole specifically blocks inactivated Na channels in myelinated nerve fibre. Pflugers Arch. (1991) 419:603–609.
- MAGYAR K, SZENDE B, LENGYEL J, TARCZALI J, SZATMARY I: The neuroprotective and neuronal rescue effects of (-)-deprenyl. J. Neural. Transm. Suppl. (1998) 52:109–123.
- TATTON WG, CHALMERS-REDMAN RM, JU WY, WADIA J, TATTON NAJ: Apoptosis in neurodegenerative disorders: potential for therapy by modifying gene transcription. Neural. Transm. Suppl. (1997) 49:245–268.
- KRAGTEN E, LALANDE I, ZIMMERMANN K et al.: Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(-)-deprenyl. J. Biol. Chem. (1998) 2 73(105821–5828.
- Novel furan sulphonic acid derivatives for the treatment of neurodegenerative and immunoinflam-matory disorders. Exp Opin. Ther. Patents (1999) 9(10):1427–1429.
- FOSTER BA, COFFEY HA, MORIN MJ, RASTINEJAD F: Pharmacological rescue of mutant p53 conformation and function. Science (1999) 286:2507–2510.
- •Supports the novel concept of therapy by conformational stabilisation.
- XU X, YANG D, WYSS-CORAY T et al.: Wild-type but not Alzheimer-mutant amyloid precursor protein confers resistance against p53-mediated apoptosis. Proc. Natl. Acad. Sci. USA (1999) 96(13):7547–7552.
- LEIST M, SINGLE B, CASTOLDI AF, KUHNLE S, NICOTERA P: Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis. J. Exp. Med. (1997) 185(8):1481–1486.
- EGUCHI Y, SHIMIZU S, TSUJIMOTO Y: Intracellular ATP levels determine cell death fate by apoptosis or necrosis. Cancer Res. (1997) 57:1835–1840.
- GARLAND JM, HALESTRAP A: Energy metabolism during apoptosis. J. Biol. Chem. (1997) 272:4680–4688.
- KAN 0, BALDWIN SA, WHETTON AD: Apoptosis is regulated by the rate of glucose transport in an Interleukin 3 dependent cell line. J. Exp. Med. (1994) 180:917–923.
- HARRISON PM, CHAN HS, PRUSINER SB, COHEN FE: Thermodynamics of model prions and its implica-tions for the problem of prion protein folding. J. Mol. Biol. (1999), 286 (2) :593–606.
- PAIK SR, SHIN HJ, LEE JH, CHANG CS, KIM J: Copper OD -induced self-oligomerization of alpha-synuclein. Biochem. J. (1999) 340 (Pt 3):821–828.
- EL-AGNAF OM, JAKES R, CURRAN MD et al: Aggregates from mutant and wild-type alpha-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of beta-sheet and amyloid-like filaments. FEBSLett. (1998) 440(1–2)71–75.
- MARKESBERY WR, CARNEY JM: Oxidative alterations in Alzheimer's disease. Brain. Pathol. (1999) 9 (1) :133–146.
- MCGEER PL, MCGEER EG: Mechanisms of cell death in Alzheimer's disease - immunopathology. J. Neural. Transm. Suppl. (1998) 54:159–166.
- GUEGAN C, CEBALLOS-PICOT I, CHEVALIER E, NICOLE A, ONTENIENTE B, SOLA B: Reduction of ischemic damage in NGF-transgenic mice: correlation with enhance-ment of antioxidant enzyme activities. Neurobiol. Dis. (1999) 6(3):180–189.
- CRUZ-AGUADO R, FRANCIS-TURNER L, DIAZ-SUAREZ CM, BERGADO J: NGF prevents changes in rat brain glutathione-related enzymes following transection of the septohippocampal pathway. Neurochem. Int. (1999) 34 (2) :125–130.
Websites
- http://parkinson.org/clnindex.htm
- http://www.parkinson.org/cox2.htm